Cargando…

A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma

Background: Hepatocellular Carcinoma (HCC) is an aggressive tumor with an inferior prognosis. Necroptosis is a new form of programmed death that plays a dual effect on the tumor. However, the role of necroptosis-related genes(NRGs) in HCC remains unknown. Methods: All datasets were downloaded from p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Xing, Yang, Yuling, Zhang, Xiaozhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484537/
https://www.ncbi.nlm.nih.gov/pubmed/36134033
http://dx.doi.org/10.3389/fgene.2022.919599
_version_ 1784791896456953856
author Fu, Xing
Yang, Yuling
Zhang, Xiaozhi
author_facet Fu, Xing
Yang, Yuling
Zhang, Xiaozhi
author_sort Fu, Xing
collection PubMed
description Background: Hepatocellular Carcinoma (HCC) is an aggressive tumor with an inferior prognosis. Necroptosis is a new form of programmed death that plays a dual effect on the tumor. However, the role of necroptosis-related genes(NRGs) in HCC remains unknown. Methods: All datasets were downloaded from publicly available databases. The consensus clustering analysis was used to classify patients into different subtypes based on NRGs. The Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression were used to develop a prognostic signature. Tumor Immune Dysfunction and Exclusion (TIDE) was used to predict immunotherapy response. Results: The genetic and transcriptional changes of NRGs were observed in HCC. Patients were classified into three clusters based on differentially expressed NRGs, of which Cluster-3 had the worst prognosis and the highest immune infiltration. The prognostic signature was developed based on 8-NRGs, which have shown excellent prognostic performance. The high-risk group in the signature presented significantly higher immune infiltration, such as aDCs, iDCs, macrophages, and Treg, compared to the low-risk group. TMB and immune checkpoints were also higher in the high-risk group. Moreover, a lower TIDE score was observed in the high-risk group, indicating the patients with high risk-score may be suitable for immunotherapy. Via the dataset of IMvigor210, we found a higher risk score in the immunotherapy response group. Conclusion: We developed a new necroptosis-related signature for predicting prognosis with the potential to predict immunotherapy for HCC patients.
format Online
Article
Text
id pubmed-9484537
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94845372022-09-20 A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma Fu, Xing Yang, Yuling Zhang, Xiaozhi Front Genet Genetics Background: Hepatocellular Carcinoma (HCC) is an aggressive tumor with an inferior prognosis. Necroptosis is a new form of programmed death that plays a dual effect on the tumor. However, the role of necroptosis-related genes(NRGs) in HCC remains unknown. Methods: All datasets were downloaded from publicly available databases. The consensus clustering analysis was used to classify patients into different subtypes based on NRGs. The Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression were used to develop a prognostic signature. Tumor Immune Dysfunction and Exclusion (TIDE) was used to predict immunotherapy response. Results: The genetic and transcriptional changes of NRGs were observed in HCC. Patients were classified into three clusters based on differentially expressed NRGs, of which Cluster-3 had the worst prognosis and the highest immune infiltration. The prognostic signature was developed based on 8-NRGs, which have shown excellent prognostic performance. The high-risk group in the signature presented significantly higher immune infiltration, such as aDCs, iDCs, macrophages, and Treg, compared to the low-risk group. TMB and immune checkpoints were also higher in the high-risk group. Moreover, a lower TIDE score was observed in the high-risk group, indicating the patients with high risk-score may be suitable for immunotherapy. Via the dataset of IMvigor210, we found a higher risk score in the immunotherapy response group. Conclusion: We developed a new necroptosis-related signature for predicting prognosis with the potential to predict immunotherapy for HCC patients. Frontiers Media S.A. 2022-09-05 /pmc/articles/PMC9484537/ /pubmed/36134033 http://dx.doi.org/10.3389/fgene.2022.919599 Text en Copyright © 2022 Fu, Yang and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Fu, Xing
Yang, Yuling
Zhang, Xiaozhi
A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
title A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
title_full A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
title_fullStr A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
title_full_unstemmed A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
title_short A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
title_sort necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484537/
https://www.ncbi.nlm.nih.gov/pubmed/36134033
http://dx.doi.org/10.3389/fgene.2022.919599
work_keys_str_mv AT fuxing anecroptosisrelatedsignatureforpredictingprognosisandimmunotherapyinhepatocellularcarcinoma
AT yangyuling anecroptosisrelatedsignatureforpredictingprognosisandimmunotherapyinhepatocellularcarcinoma
AT zhangxiaozhi anecroptosisrelatedsignatureforpredictingprognosisandimmunotherapyinhepatocellularcarcinoma
AT fuxing necroptosisrelatedsignatureforpredictingprognosisandimmunotherapyinhepatocellularcarcinoma
AT yangyuling necroptosisrelatedsignatureforpredictingprognosisandimmunotherapyinhepatocellularcarcinoma
AT zhangxiaozhi necroptosisrelatedsignatureforpredictingprognosisandimmunotherapyinhepatocellularcarcinoma